SEC Form 4 · accession 0001171843-16-010367
Xenon Pharmaceuticals Inc. · XENE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael R Hayden
Director
Period of report
May 25, 2016
Accepted (ET)
May 27, 2016 · 5:07 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001582313
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common SharesF1,F3 | May 25, 2016 | M | 8,230 | $3.30 | A | 18,518 | I | By Genworks Inc. |
| Common Shares | holding | — | — | — | 75,886 | I | By wife | |
| Common Shares | holding | — | — | — | 97,319 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3,F1,F2 | $3.30 | May 25, 2016 | M | 8,230 | D | — | Jul 31, 2016 | Common Shares | 8,230 | 0 | I |
Explanation of responses
- F1The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise.
- F2The shares subject to the option fully vested on July 31, 2010.
- F3Michael Hayden is the president and principal beneficial shareholder of Genworks Inc.